Keros Therapeutics concludes strategic review, plans $375M capital return

Keros Therapeutics, Inc.

Board unanimously approved $375M excess capital return to stockholders; structure and terms to be announced.
Strategic review included evaluation of sale, business combination, and continued investment; outreach to third parties and stockholders.
Company to continue development of lead candidate KER-065 for Duchenne muscular dystrophy.
2025 annual meeting results: all three director nominees elected, Deloitte & Touche ratified, executive compensation approved.

item 5.07item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.